Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2020
Thin endometrium problem in IVF programs.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vartanyan Emma, Tsaturova Kristina, Devyatova Ekaterina
Аннотация
METHODS: Observational, comparative, prospective, multicenter study (n = 425). Group 1 (n = 228) received estradiol hemihydrate (Divigel, Orion Corporation, Finland), group 2 (n = 197) received oral estradiol valerate (Proginova, Delpharm Lille, France).
RESULTS: An increase in endometrial thickness was comparable (10.1 (2.0) mm versus 10.0 (2.3) mm; p = .571). There was significantly shorter mean duration of estrogen therapy (13.9 (3.9) days versus 14.7 (4.7) days; p = .038) and lower total dose in group 1 (43.6 (27.3) mg versus (71.9 (37.2) mg; p = .0001). Pregnancy rates were comparable (143/228 (62.7%) versus 105/197 (53.3%); p = .077) so as "take home baby" rates (80/228 (35.1%) versus 68/197 (34.5%); p = .077).
CONCLUSION: Estrogens improve the state of the endometrium and increase pregnancy rates in cases of thin endometrium in in vitro fertilization programs. The use of transdermal estrogens (Divigel, Orion Corporation, Finland) ensures an adequate increase in endometrial thickness and significantly lower estrogen doses.
RESULTS: An increase in endometrial thickness was comparable (10.1 (2.0) mm versus 10.0 (2.3) mm; p = .571). There was significantly shorter mean duration of estrogen therapy (13.9 (3.9) days versus 14.7 (4.7) days; p = .038) and lower total dose in group 1 (43.6 (27.3) mg versus (71.9 (37.2) mg; p = .0001). Pregnancy rates were comparable (143/228 (62.7%) versus 105/197 (53.3%); p = .077) so as "take home baby" rates (80/228 (35.1%) versus 68/197 (34.5%); p = .077).
CONCLUSION: Estrogens improve the state of the endometrium and increase pregnancy rates in cases of thin endometrium in in vitro fertilization programs. The use of transdermal estrogens (Divigel, Orion Corporation, Finland) ensures an adequate increase in endometrial thickness and significantly lower estrogen doses.